This study explores the relationship between different ART therapy based on NRTIs, and inflammatory markers, along with fasting blood glucose levels in treatment-naïve people living with HIV (PLWH).
Methods
We retrospectively analyzed the variations in fasting blood glucose and inflammatory markers and their relationship with different ART regimens in 497 treatment-naïve PLWH at the ART clinic of Zhongnan Hospital of Wuhan University from June 2018 to March 2022.
Results
From baseline to 24 months, fasting blood glucose, systemic immune-inflammation index (SII), pan-immune-inflammation value (PIV) and lymphocyte-to-monocyte ratio (LMR) in PLWH receiving ART increased, while neutrophillymphocyte ratio (NLR) decreased (p < .05). In the NNRTIs group, fasting blood glucose, SII, PIV and LMR were higher than before (p < .05). In the INSTIs group, fasting blood glucose and LMR increased (p < .05), while NLR was lower (p < .05). Compared to the INSTIs, fasting blood glucose in the NNRTIs group was higher at 12 and 24 months (p < .05). At 24 months, both NLR and SII were higher in the NNRTIs group than in the INSTIs group (p < .05).
Conclusions
Despite the virus suppression, fasting blood glucose and certain inflammatory markers in PLWH can gradually increase. Compared to NNRTIs, the INSTIs regimen was associated with favorable alterations in the levels of glucose and inflammatory markers.
MinAKFortuneTRodriguezN, et al.Inflammasomes as mediators of inflammation in HIV-1 infection. Transl Res2023; 252: 1–8. DOI: 10.1016/j.trsl.2022.07.008.
2.
HsuePYWatersDD. HIV infection and coronary heart disease: mechanisms and management. Nat Rev Cardiol2019; 16(12): 745–759. DOI: 10.1038/s41569-019-0219-9.
3.
CaoWHsiehELiT. Optimizing treatment for adults with HIV/AIDS in China: successes over two decades and remaining challenges. Curr HIV AIDS Rep2020; 17(1): 26–34. DOI: 10.1007/s11904-019-00478-x.
4.
FeinsteinMJHsuePYBenjaminLA, et al.Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American heart association. Circulation2019; 140(2): e98–e124. DOI: 10.1161/CIR.0000000000000695.
5.
VosAGChersichMFKlipstein-GrobuschK, et al.Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir. Retrovirology2018; 15(1): 77. DOI: 10.1186/s12977-018-0460-z.
6.
SmitMBrinkmanKGeerlingsS, et al.Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis2015; 15(7): 810–818. DOI: 10.1016/S1473-3099(15)00056-0.
7.
RidkerPMCushmanMStampferMJ, et al.Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med1997; 336(14): 973–979. DOI: 10.1056/NEJM199704033361401.
8.
DaneshJWheelerJGHirschfieldGM, et al.C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med2004; 350(14): 1387–1397. DOI: 10.1056/NEJMoa032804.
9.
RidkerPMRifaiNRoseL, et al.Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med2002; 347(20): 1557–1565. DOI: 10.1056/NEJMoa021993.
10.
VosAGIdrisNSBarthRE, et al.Pro-inflammatory markers in relation to cardiovascular disease in HIV infection. A systematic review. PLoS One2016; 11(1): e0147484. DOI: 10.1371/journal.pone.0147484.
11.
TenorioARZhengYBoschRJ, et al.Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis2014; 210(8): 1248–1259. DOI: 10.1093/infdis/jiu254.
12.
NordellADMcKennaMBorgesÁH, et al.Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc2014; 3(3): e000844. DOI: 10.1161/JAHA.114.000844.
13.
RossACRizkNO’RiordanMA, et al.Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis2009; 49(7): 1119–1127. DOI: 10.1086/605578.
14.
HarbolAWLiesveldJLSimpson-HaidarisPJ, et al.Mechanisms of cytopenia in human immunodeficiency virus infection. Blood Rev1994; 8(4): 241–251. DOI: 10.1016/0268-960x(94)90112-0.
15.
BallemPJBelzbergADevineDV, et al.Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med1992; 327(25): 1779–1784. DOI: 10.1056/NEJM199212173272503.
16.
MofensonLMHarrisDRMoyeJ, et al.Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings. Lancet Lond Engl2003; 362(9396): 1625–1627. DOI: 10.1016/S0140-6736(03)14825-8.
17.
MadzimeMRossouwTMTheronAJ, et al.Interactions of HIV and antiretroviral therapy with neutrophils and platelets. Front Immunol2021; 12: 634386. DOI: 10.3389/fimmu.2021.634386.
18.
Quiros-RoldanERaffettiEDonatoF, et al.Neutrophil to lymphocyte ratio and cardiovascular disease incidence in HIV-infected patients: a population-based cohort study. PLoS One2016; 11(5): e0154900. DOI: 10.1371/journal.pone.0154900.
19.
MuratSNYarliogluesMCelikIE, et al.The relationship between lymphocyte-to-monocyte ratio and bare-metal stent in-stent restenosis in patients with stable coronary artery disease. Clin Appl Thromb Hemost2017; 23(3): 235–240. DOI: 10.1177/1076029615627340.
20.
LiuYYeTChenL, et al.Systemic immune-inflammation index predicts the severity of coronary stenosis in patients with coronary heart disease. Coron Artery Dis2021; 32(8): 715–720. DOI: 10.1097/MCA.0000000000001037.
21.
KurtulAMuratSNYarliogluesM, et al.Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes. Am J Cardiol2014; 114(7): 972–978. DOI: 10.1016/j.amjcard.2014.07.005.
22.
MuratBMuratSOzgeyikM, et al.Comparison of pan-immune-inflammation value with other inflammation markers of long-term survival after ST-segment elevation myocardial infarction. Eur J Clin Invest2023; 53(1): e13872. DOI: 10.1111/eci.13872.
23.
GordhanbhaiPSRavindraTSYeldoD. Association between neutrophil-to-lymphocyte ratio and severity of coronary artery disease. APIK J Intern Med2023; 11(3): 171–178. DOI: 10.4103/ajim.ajim_92_22.
24.
ElzarkiAFNandulaSRAwalH, et al.Cardiovascular disease (CVD) risk assessment of HIV medication regimens using hematopoietic CD34+ progenitor cells. Stem Cell Res Ther2022; 13(1): 103. DOI: 10.1186/s13287-022-02775-6.
25.
CaoYLiPZhangY, et al.Association of systemic immune inflammatory index with all-cause and cause-specific mortality in hypertensive individuals: results from NHANES. Front Immunol2023; 14: 1087345. DOI: 10.3389/fimmu.2023.1087345.
26.
TangjitgamolSUdayachalermWWanishsawadC, et al.Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and coronary artery disease among the physicians. J Inflamm Res2024; 17: 59–66. DOI: 10.2147/JIR.S447750.
27.
McGettrickPMallonPWG. Biomarkers to predict cardiovascular disease in people living with HIV. Curr Opin Infect Dis2022; 35(1): 15–20. DOI: 10.1097/QCO.0000000000000802.
28.
YousefpouranSMostafaeiSManeshPV, et al.The assessment of selected MiRNAs profile in HIV, HBV, HCV, HIV/HCV, HIV/HBV Co-infection and elite controllers for determination of biomarker. Microb Pathog2020; 147: 104355. DOI: 10.1016/j.micpath.2020.104355.
29.
Sadri NahandJBokharaei-SalimFKarimzadehM, et al.MicroRNAs and exosomes: key players in HIV pathogenesis. HIV Med2020; 21(4): 246–278. DOI: 10.1111/hiv.12822.
30.
SlamaLBarrettBWAbrahamAG, et al.Risk for incident diabetes is greater in prediabetic men with HIV than without HIV. AIDS Lond Engl2021; 35(10): 1605–1614. DOI: 10.1097/QAD.0000000000002922.
31.
TadesseWTAdankieBTShibeshiW, et al.Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy. PLoS One2022; 17(1): e0262604. DOI: 10.1371/journal.pone.0262604.
32.
RebeiroPFJenkinsCABianA, et al.Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada. Clin Infect Dis Off Publ Infect Dis Soc Am2021; 73(7): e2234–e2242. DOI: 10.1093/cid/ciaa1403.
33.
LamordeMAtwiineMOwarwoNC, et al.Dolutegravir-associated hyperglycaemia in patients with HIV. Lancet HIV2020; 7(7): e461–e462. DOI: 10.1016/S2352-3018(20)30042-4.
34.
SaxPEErlandsonKMLakeJE, et al.Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis2020; 71(6): 1379–1389. DOI: 10.1093/cid/ciz999.
35.
BourgiKRebeiroPFTurnerM, et al.Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy. Clin Infect Dis2020; 70(7): 1267–1274. DOI: 10.1093/cid/ciz407.
36.
VenterWDFMoorhouseMSokhelaS, et al.Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med2019; 381(9): 803–815. DOI: 10.1056/NEJMoa1902824.
37.
HsuDCSeretiIAnanworanichJ. Serious Non-AIDS events: immunopathogenesis and interventional strategies. AIDS Res Ther2013; 10(1): 29. DOI: 10.1186/1742-6405-10-29.
38.
HearpsACMartinGERajasuriarR, et al.Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing. Curr HIV AIDS Rep2014; 11(1): 20–34. DOI: 10.1007/s11904-013-0190-8.
39.
FrenchMACozzi-LepriAArduinoRC, et al.Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial. AIDS Lond Engl2015; 29(7): 847–851. DOI: 10.1097/QAD.0000000000000618.
40.
RaffettiEDonatoFCasariS, et al.Systemic inflammation-based scores and mortality for all causes in HIV-infected patients: a MASTER cohort study. BMC Infect Dis2017; 17(1): 193. DOI: 10.1186/s12879-017-2280-5.
41.
MasyukoSJPageSTPolyakSJ, et al.Human immunodeficiency virus is associated with higher levels of systemic inflammation among Kenyan adults despite viral suppression. Clin Infect Dis2021; 73(7): e2034–e2042. DOI: 10.1093/cid/ciaa1650.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
